Dr. Guo-Liang Yu is a co-founder of Apollomics, Inc. He is a venture partner at Orbimed Venture LLC and the Executive Chairman of Crown Bioscience Inc. Dr. Yu co-founded Epitomics Inc., an antibody-based Biotechnology Company recently acquired by Abcam at $170 M. He served as Chairman, President and CEO of Epitomics Inc. for 10 years. Dr. Yu’s success is driven by his scientific curiosity and a passion for translating scientific discovery to real products. His challenge is to balance his time between science and business, fun and work, family and community.

He moved from China to the US to pursue advanced training after graduating from Fudan University in 1984. He obtained his PhD from UC Berkeley where he contributed to the discovery of telomerase and its mechanism of action in Dr. Blackburn’s lab. Drs. Blackburn and Greider received the Nobel Prize in 2009 for their discovery. After graduating, Dr. Yu joined Dr. Frederick Ausubel’s lab at Harvard to pursue the question of how plants defend themselves against pathogens without an immune system. He identified the first plant disease resistance gene.

Dr. Sanjeev Redkar is a co-founder of Apollomics, Inc. that was started as a spin-off in early 2016. In his previous role, Dr. Redkar was the Senior Vice President of Product Development at Astex Pharmaceuticals, a member of the Otsuka Group, where he was responsible for pharmaceutical development, technical operations and manufacturing. Dr. Redkar has been closely involved in preclinical and clinical development as well as global launches of several drugs including decitabine (Dacogen) and pentostatin (Nipent).

Dr. Redkar has over 24 years of oncology drug development experience with over 25 peer-reviewed publications and 150 patents. Dr. Redkar earned his doctorate from the University of Colorado, Boulder, his Master of Business Administration from St. Mary’s College of California, and his undergraduate degree at the Indian Institute of Technology, Bombay. He is a member of the Industrial Advisory Board at the University of the Pacific School of Pharmacy in Stockton, California, and a member of the EPPIC Board of Directors, a pharmaceutical professional’s network.

Dr. Kin-Hung Peony Yu joined Apollomics in 2021 as Chief Medical Officer. Dr. Peony Yu will be providing leadership to R&D and be primarily responsible for clinical development of our products. She has over 25 years of experience in pharmaceutical leadership, patient care and drug development, with expertise in clinical regulatory strategy and execution of clinical programs of innovative biopharmaceuticals.

Previoulsy, Dr. Yu worked for FibroGen, Inc. (NASDAQ: FGEN) as a vice president until her designation as CMO. Dr. Peony Yu previously served as the vice president and head of clinical research at Anesiva, Inc., formerly known as Corgentech, Inc., (NASDAQ: ANSV). She obtained an M.D. degree from the University of California, Davis School of Medicine, in the U.S. She completed her residency training at Stanford University School of Medicine in the U.S. Dr. Peony Yu has authored or co-authored 12 peer-reviewed publications. Dr. Peony Yu holds a medical license registered in California.

Dr. Peony Yu is an independent nonexecutive director at STAAR Surgical Company (NASDAQ: STAA). She is also on the Scientific Advisory Board of Hope Medicine Inc. and she is a member of the Scientific Advisory Board of BeyondSpring Inc. (NASDAQ: BYSI).

Wilson W. Cheung joined Apollomics in 2019 and brings over 25 years of experience in finance, compliance, and corporate leadership at both public and private companies. Prior to Apollomics, Mr. Cheung was CFO of KBP BioSciences, a clinical stage biotechnology company, and an Independent Director of SciClone Pharmaceuticals International Limited, a China-based US-listed specialty pharmaceutical company. At SciClone, Mr. Cheung was Senior Vice President and CFO where he helped turn around the company’s compliance culture and drove the company’s growth and profitability which led to a successful sale.

Previously, he served in various positions at Velti plc, a global mobile marketing software-as-a-service provider, and led their Nasdaq Initial Public Offering as CFO. Prior to Velti, Mr. Cheung served as CFO at AXT, Inc., a California-based, publicly traded manufacturer of high-performance semiconductor substrates with heavy China operations. As a Certified Public Accountant (CPA), he began his career in public accounting with KPMG LLP and Deloitte LLP. Mr. Cheung holds a B.A. degree from the University of California, Los Angeles (UCLA), and is a Certified Director of Corporate Governance from UCLA’s Executive Program. He is a member of the American Institute of Certified Public Accountants, and he is a California CPA (inactive).

Dr. Chinglin Lai joined Apollomics in 2021 as the Senior Vice President of Biometrics. Dr. Lai has over 27 years of experience in drug development across a broad range of therapeutic areas. His experience is primarily in first-in-human studies through late-stage development for marketing approvals. Prior to Apollomics, Dr. Lai was a consultant providing statistical expertise to over 20 emerging and established pharmaceutical and biotech companies in the US and Asia. Previously, Dr. Lai held leadership positions at Jazz Pharmaceuticals, overseeing biostatistics, statistical programming, and data management functions for all portfolio products. Prior to Jazz, he worked at Intrabiotics Pharmaceuticals (2004-2005) and was a member of the core team for evaluating in-licensing opportunities, and Alza Corporation, where he contributed to the marketing approvals of 5 products in the US and EU. Dr. Lai received his B.S. in Mathematics from National Central University in Taiwan, and Ph.D. in Applied Statistics from the University of California, Riverside, with a concentration in experimental design.

Sophie Sun is the Senior Vice President of Corporate Development, in charge of corporate strategy, business development and strategic collaboration for the Company.  Ms. Sun joins Apollomics from Merck KGaA, where she was most recently Vice President & Managing Director, Innovation Hubs China.  In this role, Ms. Sun oversaw Merck KGaA’s development partnerships in China for China and global markets.  She was with Merck KGaA for twelve years holding multiple roles of increasing responsibility in both strategic markets of China and US, as well as global organizations, such as Commercial Director of Global Oncology Franchise for oncology new product planning and launch.  During her tenure with Merck KGaA, Sophie participated in 9 new product launches in China, US locally or for global markets. Prior to Merck KGaA, Ms. Sun spent over eight years at marketing agencies Interpublic Group (IPG) and WPP, where she worked for many Fortune 500 companies covering a wide range of industries. Ms. Sun received a Master degree from Remin University of China, and a Master of Business Administration from MIT Sloan School of Management.